This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (111)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Obesity  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Alfred Wirth, MD; Jutta Krause

JAMA. 2001;286:1331-1339.

Context  Treatment of obesity requires long-term therapy, which can be hampered by difficulties in achieving patient compliance. The effectiveness of sibutramine hydrochloride in treating obesity has been shown in randomized controlled trials.

Objective  To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons.

Design  Randomized, double-blind, parallel-group placebo-controlled trial from April 1997 to September 1998.

Setting  One hundred eight private practices and 3 outpatient departments of university hospitals in Germany.

Patients  A total of 1102 obese adults (body mass index, 30-40 kg/m²) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period.

Interventions  Patients were randomly assigned to receive 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405); 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48, with placebo during all other weeks (n = 395); or placebo for weeks 5-48 (n = 201).

Main Outcome Measure  Weight loss during the randomized treatment period, compared among all 3 groups.

Results  Mean weight loss in the intention-to-treat population during the 44-week randomized treatment period was 3.8 kg (4.0%) in patients receiving continuous therapy (95% confidence interval [CI], - 4.42 to - 3.20 kg) and was 3.3 kg (3.5%) in patients receiving intermittent therapy (95% CI, - 3.96 to - 2.66 kg), vs a mean weight gain of 0.2 kg (0.2%) (95% CI, - 0.60 to 0.94 kg) in patients receiving placebo. Therapeutic equivalence of the 2 active treatments could be shown. Although there was a greater weight loss in the continuous than in the intermittent group, this difference was nonsignificant (P = .28) and the 95% CIs were within the predefined range of therapeutic equivalence—0 ±1.5 kg (-1.37 to 0.28 for the intent-to-treat population). Overall weight loss during the 48-week period was 7.9 kg and 7.8 kg in the continuous and intermittent groups, respectively, but was 3.8 kg in the sibutramine run-in placebo group. Waist circumference reduction, triglyceride levels, and high-density lipoprotein cholesterol concentrations were also positively influenced by sibutramine treatment. Systolic and diastolic blood pressures were stable across all 3 groups. Overall, adverse events occurred at similar frequencies across all treatment groups, but the proportion was lowest in the group receiving intermittent therapy.

Conclusions  Sibutramine, administered for 48 weeks to a typically obese population, results in clinically relevant weight loss compared with placebo. Regarding effectiveness, continuous and intermittent sibutramine therapies are equivalent and the safety profiles for both treatments are comparable.

Author Affiliations: Teutoburger-Wald-Klinik, Bad Rothenfelde (Dr Wirth) and Knoll Deutschland GmbH Klinische Prüfungen, Ludwigshafen (Ms Krause), Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Measuring the Effect of Sibutramine for Weight Loss
Thomas Ransom, Ehud Ur, and Alfred Wirth
JAMA. 2002;287(4):449-450.
EXTRACT | FULL TEXT  

RELATED ARTICLE

September 19, 2001
JAMA. 2001;286(11):1389-1390.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich et al.
Ther Adv Cardiovasc Dis 2009;3:75-90.
ABSTRACT  

Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety
Bray
J. Clin. Endocrinol. Metab. 2008;93:s81-s88.
ABSTRACT | FULL TEXT  

Weight management and cardiovascular disease: implications of recent and ongoing clinical trials
Wilding and Finer
British Journal of Diabetes & Vascular Disease 2008;8:170-176.
ABSTRACT  

Treatment Modalities of Obesity: What fits whom?
Hainer et al.
Diabetes Care 2008;31:S269-S277.
ABSTRACT | FULL TEXT  

Binge Eating Disorder: The Search for Better Treatments
Yager
Am. J. Psychiatry 2008;165:4-6.
FULL TEXT  

Review: Pharmacotherapy as part of a weight management programme: a UK perspective
Barnett
British Journal of Diabetes & Vascular Disease 2007;7:268-277.
ABSTRACT  

State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant
Dunican et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:367-388.
ABSTRACT  

Pharmacotherapeutic Options for Overweight Adolescents
Dunican et al.
The Annals of Pharmacotherapy 2007;41:1445-1455.
ABSTRACT | FULL TEXT  

Pharmacological Treatment of the Overweight Patient
Bray and Greenway
Pharmacol. Rev. 2007;59:151-184.
FULL TEXT  

Optimal Treatment of Obesity-Related Hypertension: The Hypertension-Obesity-Sibutramine (HOS) Study
Scholze et al.
Circulation 2007;115:1991-1998.
ABSTRACT | FULL TEXT  

Exposure to sibutramine during pregnancy
Garcia-Bournissen et al.
cfp 2007;53:229-230.
ABSTRACT | FULL TEXT  

Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective
Heymsfield et al.
Am. J. Clin. Nutr. 2007;85:346-354.
ABSTRACT | FULL TEXT  

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT  

Obesity Research--Limitations of Methods, Measurements, and Medications
Simons-Morton et al.
JAMA 2006;295:826-828.
FULL TEXT  

Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society
Villareal et al.
Am. J. Clin. Nutr. 2005;82:923-934.
ABSTRACT | FULL TEXT  

The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients
James
Eur Heart J Suppl 2005;7:L44-L48.
ABSTRACT | FULL TEXT  

Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions
McIntyre and Konarski
Focus 2005;3:511-519.
ABSTRACT | FULL TEXT  

A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
Henderson et al.
Am. J. Psychiatry 2005;162:954-962.
ABSTRACT | FULL TEXT  

Meta-Analysis: Pharmacologic Treatment of Obesity
Li et al.
ANN INTERN MED 2005;142:532-546.
ABSTRACT | FULL TEXT  

Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes: A meta-analysis of clinical studies
Vettor et al.
Diabetes Care 2005;28:942-949.
ABSTRACT | FULL TEXT  

Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Klein et al.
Circulation 2004;110:2952-2967.
ABSTRACT | FULL TEXT  

Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals
Wood et al.
Clin Trials 2004;1:368-376.
ABSTRACT  

The Efficacy and Safety of Sibutramine for Weight Loss: A Systematic Review
Arterburn et al.
Arch Intern Med 2004;164:994-1003.
ABSTRACT | FULL TEXT  

Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force
McTigue et al.
ANN INTERN MED 2003;139:933-949.
ABSTRACT | FULL TEXT  

Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial)
van Baak et al.
Am. J. Clin. Nutr. 2003;78:209-214.
ABSTRACT | FULL TEXT  

Pharmacological Therapy of Obesity: Past, Present, and Future
Weigle
J. Clin. Endocrinol. Metab. 2003;88:2462-2469.
FULL TEXT  

Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults: A Randomized, Dose-Ranging Study
Ettinger et al.
JAMA 2003;289:1826-1832.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance: A Meta-analysis
Shekelle et al.
JAMA 2003;289:1537-1545.
ABSTRACT | FULL TEXT  

Obesity: Overview of Prevalence, Etiology, and Treatment
Racette et al.
ptjournal 2003;83:276-288.
FULL TEXT  

OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT  

Obesity Research: A Call for Papers
Fontanarosa
JAMA 2002;288:1772-1773.
FULL TEXT  

Sibutramine update
Day and Bailey
British Journal of Diabetes & Vascular Disease 2002;2:392-397.
ABSTRACT  

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias
Wooltorton
CMAJ 2002;166:1307-1308.
FULL TEXT  

Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obesity
Cheskin
Evid. Based Med. 2002;7:46-46.
FULL TEXT  

Obesity
Yanovski and Yanovski
NEJM 2002;346:591-602.
FULL TEXT  

Measuring the Effect of Sibutramine for Weight Loss
Ransom et al.
JAMA 2002;287:449-450.
FULL TEXT  

Effectiveness of Intermittent Sibutramine for Weight Loss
JWatch General 2001;2001:6-6.
FULL TEXT